GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Geovax Labs Inc (NAS:GOVX) » Definitions » Cyclically Adjusted FCF per Share

GOVX (Geovax Labs) Cyclically Adjusted FCF per Share : $0.00 (As of Mar. 2025)


View and export this data going back to 2020. Start your Free Trial

What is Geovax Labs Cyclically Adjusted FCF per Share?

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted FCF per Share and the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years.

Geovax Labs's adjusted free cash flow per share for the three months ended in Mar. 2025 was $-0.500. Add all the adjusted free cash flow per share for the past 10 years together and divide the count will get our Cyclically Adjusted FCF per Share, which is $0.00 for the trailing ten years ended in Mar. 2025.

During the past 3 years, the average Cyclically Adjusted FCF Growth Rate was 1.90% per year. During the past 5 years, the average Cyclically Adjusted FCF Growth Rate was -1.10% per year. During the past 10 years, the average Cyclically Adjusted FCF Growth Rate was -6.80% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted FCF Growth Rate using Cyclically Adjusted FCF per Share data.

During the past 13 years, the highest 3-Year average Cyclically Adjusted FCF Growth Rate of Geovax Labs was 16.90% per year. The lowest was -21.30% per year. And the median was 0.20% per year.

As of today (2025-05-11), Geovax Labs's current stock price is $0.9276. Geovax Labs's Cyclically Adjusted FCF per Share for the quarter that ended in Mar. 2025 was $0.00. Geovax Labs's Cyclically Adjusted Price-to-FCF of today is .


Geovax Labs Cyclically Adjusted FCF per Share Historical Data

The historical data trend for Geovax Labs's Cyclically Adjusted FCF per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Geovax Labs Cyclically Adjusted FCF per Share Chart

Geovax Labs Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Cyclically Adjusted FCF per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only -70.37 -77.24 -77.43 -76.59 -72.82

Geovax Labs Quarterly Data
Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25
Cyclically Adjusted FCF per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -76.78 -75.51 -74.53 -72.82 -

Competitive Comparison of Geovax Labs's Cyclically Adjusted FCF per Share

For the Biotechnology subindustry, Geovax Labs's Cyclically Adjusted Price-to-FCF, along with its competitors' market caps and Cyclically Adjusted Price-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Geovax Labs's Cyclically Adjusted Price-to-FCF Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Geovax Labs's Cyclically Adjusted Price-to-FCF distribution charts can be found below:

* The bar in red indicates where Geovax Labs's Cyclically Adjusted Price-to-FCF falls into.


;
;

Geovax Labs Cyclically Adjusted FCF per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted FCF per Share and the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years.

What is Cyclically Adjusted FCF per Share? How do we calculate Cyclically Adjusted FCF per Share?

Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted FCF per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the free cash flow per share from 2001 through 2010.

We adjusted the 2001 free cash flow per share data with the total inflation from 2001 through 2010 to the equivalent free cash flow in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's free cash flow is $1 a share in 2001, then the 2001's equivalent free cash flow in 2010 is $1.4 a share. If Wal-Mart's free cash flow is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 free cash flow in 2010 is $1.35. So on and so forth, you get the equivalent free cash flow per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted FCF per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Geovax Labs's adjusted Free Cash Flow per Share data for the three months ended in Mar. 2025 was:

Adj_FreeCashFlowPerShare= Free Cash Flow per Share /CPI of Mar. 2025 (Change)*Current CPI (Mar. 2025)
=-0.5/134.9266*134.9266
=-0.500

Current CPI (Mar. 2025) = 134.9266.

Geovax Labs Quarterly Data

Free Cash Flow per Share CPI Adj_FreeCashFlowPerShare
201506 -14.587 100.684 -19.548
201509 -14.239 100.392 -19.137
201512 -16.543 99.792 -22.367
201603 -13.674 100.470 -18.363
201606 -11.848 101.688 -15.721
201609 -8.761 101.861 -11.605
201612 -8.000 101.863 -10.597
201703 -7.304 102.862 -9.581
201706 -9.326 103.349 -12.175
201709 -10.413 104.136 -13.492
201712 -9.739 104.011 -12.634
201803 -8.304 105.290 -10.641
201806 -8.261 106.317 -10.484
201809 -6.087 106.507 -7.711
201812 -10.913 105.998 -13.891
201903 -6.978 107.251 -8.779
201906 -9.913 108.070 -12.377
201909 -7.478 108.329 -9.314
201912 -281.000 108.420 -349.699
202003 -22.438 108.902 -27.800
202006 -12.326 108.767 -15.290
202009 -5.442 109.815 -6.686
202012 -6.023 109.897 -7.395
202103 -4.566 111.754 -5.513
202106 -2.983 114.631 -3.511
202109 -3.863 115.734 -4.504
202112 -15.688 117.630 -17.995
202203 -9.272 121.301 -10.314
202206 -4.545 125.017 -4.905
202209 -2.462 125.227 -2.653
202212 -4.023 125.222 -4.335
202303 -2.143 127.348 -2.271
202306 -3.862 128.729 -4.048
202309 -2.879 129.860 -2.991
202312 -5.188 129.419 -5.409
202403 -2.401 131.776 -2.458
202406 -0.764 132.554 -0.778
202409 -1.452 133.029 -1.473
202412 -0.736 133.157 -0.746
202503 -0.500 134.927 -0.500

Add all the adjusted free cash flow per share together and divide 10 will get our Cyclically Adjusted FCF per Share.


Geovax Labs  (NAS:GOVX) Cyclically Adjusted FCF per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted FCF per Share may underestimate the company's free cash flow. Cyclically Adjusted Price-to-FCF can seem to be too high even the actual Price-to-Free-Cash-Flow is low.

For the Cyclically Adjusted Price-to-FCF, the free cash flow per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/FCF calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted Price-to-FCF is also called CAPFCF Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted free cash flow per share of a company over the past 10 years.


Be Aware

Cyclically Adjusted Price-to-FCF works better for cyclical companies. It gives you a better idea on the company's real free cash flow value.


Geovax Labs Cyclically Adjusted FCF per Share Related Terms

Thank you for viewing the detailed overview of Geovax Labs's Cyclically Adjusted FCF per Share provided by GuruFocus.com. Please click on the following links to see related term pages.


Geovax Labs Business Description

Industry
Traded in Other Exchanges
N/A
Address
1900 Lake Park Drive, Suite 380, Smyrna, GA, USA, 30080
Geovax Labs Inc is a clinical-stage biotechnology company developing human vaccines and immunotherapies against infectious diseases and solid tumor cancers using novel proprietary platforms. GeoVax's product pipeline includes ongoing human clinical trials for a next-generation COVID-19 vaccine and a gene-directed therapy against head and neck cancers. Additional research and development programs include preventive vaccines against Monkeypox (MPox), hemorrhagic fever viruses (Ebola Zaire, Ebola Sudan, Marburg, and Lassa), and Zika virus, as well as immunotherapies for multiple solid tumors. The Company's key clinical program is GEO-CM04S1, a next-generation COVID-19 vaccine.
Executives
Spencer John N Jr director 2859 PACES FERRY RD, STE 1000, ATLANTA GA 30339
John W. Sharkey officer: VP, Business Development 16857 E. SAGUARO BLVD., FOUNTAIN HILLS AZ 85268
David A Dodd director C/O SEROLOGICALS CORP, 5565 SPALDING DR, NORCROSS GA 30092
Mark Reynolds officer: Chief Financial Officer TWO BALA PLAZA, SUITE 300, PHILADELPHIA PA 19004
Mckee Kelly T. Jr. officer: Chief Medical Officer 233 VALLEY MEADOW DRIVE, CHAPEL HILL NC 27516
Jayne Morgan director 1900 LAKE PARK DRIVE, SUITE 380, SMYRNA GA 30080
Randal D Chase director 28 GEORGIA COURT, RICHMOND HILL A6 L4E ON7
Nicole Lemerond director 3 MURRAY HILL ROAD, SCARSDALE NY 10583
Dean G Kollintzas director 1256 BRIARCLIFF ROAD N.E., EMTECH BIO SUITE 500, ATLANTA GA 30306
Robert T Mcnally director
Farshad Guirakhoo officer: Sr VP, Research & Development 39 CHESTNUT STREET, MELROSE MA 02176
Steven S. Antebi director 10550 FONTENELLE WAY, LOS ANGELES CA 90077
Harriet L Robinson other: Chair, Scientific Adv Brd 1256 BRIARCLIFF ROAD N.E., EMTECH BIO SUITE 500, ATLANTA GA 30306
Mark J Newman officer: VP, Research & Development 1900 LAKE PARK DR, SUITE 380, SMYRNA GA 30080
Peter M Tsolinas director 123 JOAN DRIVE, BARRINGTON IL 60010